SCHEMBL4247033

SCHEMBL4247033

O=C(Nc1ccc(-c2nnc(S(=O)(=O)Cc3ccccc3)o2)c(Cl)c1)c1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.54
KCNH2 Q12809 5/20 0.54
GRM4 Q14833 1/20 0.47
SMN1; SMN2 Q16637 6/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
MAPT P10636 3/20 0.45
HPGD P15428 2/20 0.45
PTPRC P08575 2/20 0.45
CTSL P07711 1/20 0.45
PTPN1 P18031 1/20 0.45
CTSS P25774 1/20 0.45
PTPN13 Q12923 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
CHRNA1 P02708 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036871 0.92 CHRNA7 (0.52) CHRNA7KCNH2SMN1; SMN2NPC1RAB9A
SCHEMBL4243114 0.88 CHRNA7 (0.55) CHRNA7KCNH2SMN1; SMN2NPC1RAB9A
SCHEMBL4250780 0.88 RAB9A (0.47) GRM4NPC1RAB9AMAPTHPGD
SCHEMBL13878330 0.88 CHRNA7 (0.55) CHRNA7KCNH2SMN1; SMN2NPC1RAB9A
SCHEMBL4242077 0.87 CHRNA7 (0.56) CHRNA7KCNH2SMN1; SMN2NPC1RAB9A
SCHEMBL4241242 0.85 CHRNA7 (0.53) CHRNA7KCNH2MAPTMEN1KMT2A
SCHEMBL4246981 0.82 CHRNA7 (0.51) CHRNA7KCNH2SMN1; SMN2NPC1RAB9A
SCHEMBL4245363 0.81 CHRNA7 (0.55) CHRNA7KCNH2GRM4SMN1; SMN2NPC1
SCHEMBL13878319 0.80 CHRNA7 (0.59) CHRNA7KCNH2GRM4SMN1; SMN2NPC1
SCHEMBL4238834 0.79 HPGD (0.49) GRM4SMN1; SMN2MAPTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 CHRNA7 1/4885KCNH2 815/4885GRM4 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.